https://www.aequuspharma.ca https://www.aequuspharma.ca/privacy-policy https://www.aequuspharma.ca/news-releases/a-message-from-the-ceo-of-aequus-pharmaceuticals https://www.aequuspharma.ca/news-releases/a-return-to-revenue-growth-aequus-provides-second-quarter-2019-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-adds-zepto-capsulotomy-system-a-revenue-generating-product-to-commercial-ophthalmology-portfolio https://www.aequuspharma.ca/news-releases/aequus-advances-clinical-development-of-transdermal-anti-nausea-patch https://www.aequuspharma.ca/news-releases/aequus-advances-clinical-development-of-transdermal-aripiprazole-patch https://www.aequuspharma.ca/news-releases/aequus-and-camargo-complete-pre-investigational-new-drug-submission-with-fda-for-transdermal-anti-nausea-program https://www.aequuspharma.ca/news-releases/aequus-and-camargo-prepare-for-meeting-with-fda-to-advance-anti-nausea-patch https://www.aequuspharma.ca/news-releases/aequus-and-corium-enter-into-product-development-collaboration-focused-on-cns https://www.aequuspharma.ca/news-releases/aequus-and-corium-join-forces-to-advance-anti-nausea-transdermal-patch https://www.aequuspharma.ca/news-releases/aequus-and-ehave-enter-into-collaboration-agreement-for-comprehensive-patient-data-management-in-clinical-trials-of-medical-cannabis https://www.aequuspharma.ca/news-releases/aequus-and-medicom-announce-changes-to-their-respective-commercial-leadership-teams https://www.aequuspharma.ca/news-releases/aequus-and-medicom-healthcare-sign-exclusive-term-sheet-to-jointly-advance-ophthalmology-products-into-the-usa https://www.aequuspharma.ca/news-releases/aequus-and-revision-to-collaborate-on-stargardt-disease-program https://www.aequuspharma.ca/news-releases/aequus-and-scientus-agree-to-terms-for-a-medical-cannabis-commercial-supply-and-product-development-collaboration https://www.aequuspharma.ca/news-releases/aequus-announces-3-million-bought-deal-financing https://www.aequuspharma.ca/news-releases/aequus-announces-a-binding-term-sheet-for-the-marketing-and-promotion-of-transplant-products-in-canadian-market https://www.aequuspharma.ca/news-releases/aequus-announces-abbreviated-development-path-for-transdermal-aripiprazole https://www.aequuspharma.ca/news-releases/aequus-announces-advancement-of-anti-nausea-transdermal-extended-release-patent-application https://www.aequuspharma.ca/news-releases/aequus-announces-advancement-of-clobazam-transdermal-patent-application https://www.aequuspharma.ca/news-releases/aequus-announces-anne-stevens-leadership-change https://www.aequuspharma.ca/news-releases/aequus-announces-best-efforts-public-offering https://www.aequuspharma.ca/news-releases/aequus-announces-canadian-filing-of-nds-for-preservative-free-glaucoma-medications https://www.aequuspharma.ca/news-releases/aequus-announces-change-to-proposed-300-000-equity-financing https://www.aequuspharma.ca/news-releases/aequus-announces-closing-of-800-000-equity-financing https://www.aequuspharma.ca/news-releases/aequus-announces-completion-of-dosing-in-phase-1-clinical-trial-of-aripiprazole-transdermal-patch https://www.aequuspharma.ca/news-releases/aequus-announces-delay-in-filing-annual-financial-statements https://www.aequuspharma.ca/news-releases/aequus-announces-director-resignation https://www.aequuspharma.ca/news-releases/aequus-announces-expansion-of-market-opportunity-for-its-long-acting-anti-nausea-transdermal-patch https://www.aequuspharma.ca/news-releases/aequus-announces-expansion-of-medicom-partnership-and-filing-with-health-canada-for-additional-evolve-dry-eye-product https://www.aequuspharma.ca/news-releases/aequus-announces-filing-of-new-medical-device-license-for-evolve-dry-eye-products-in-canada https://www.aequuspharma.ca/news-releases/aequus-announces-filing-of-prospectus-supplement-and-an-update-to-previously-announced-public-offering-of-convertible-debenture-units https://www.aequuspharma.ca/news-releases/aequus-announces-financing-to-support-launch-of-zimed-preservative-free-bimatoprost-0-03 https://www.aequuspharma.ca/news-releases/aequus-announces-financing-to-support-launch-of-zimed-r-preservative-free-bimatoprost-0-03-and-board-update https://www.aequuspharma.ca/news-releases/aequus-announces-first-canadian-cataract-procedures-using-zepto-capsulotomy-system https://www.aequuspharma.ca/news-releases/aequus-announces-fully-subscribed-775-000-equity-financing https://www.aequuspharma.ca/news-releases/aequus-announces-giovanni-di-genova-joining-board-of-directors https://www.aequuspharma.ca/news-releases/aequus-announces-health-canada-notice-of-compliance-noc-for-zimed-r-preservative-free-bimatoprost-0-03 https://www.aequuspharma.ca/news-releases/aequus-announces-issuance-of-stock-options https://www.aequuspharma.ca/news-releases/aequus-announces-issuance-of-stock-options-06042020 https://www.aequuspharma.ca/news-releases/aequus-announces-marc-lustig-joining-board-of-directors-and-making-direct-equity-investment-into-the-company https://www.aequuspharma.ca/news-releases/aequus-announces-new-chief-commercial-officer https://www.aequuspharma.ca/news-releases/aequus-announces-new-financing https://www.aequuspharma.ca/news-releases/aequus-announces-new-financing-and-provides-launch-update-of-zimed-preservative-free-bimatoprost-0-03 https://www.aequuspharma.ca/news-releases/aequus-announces-new-independent-director-to-its-board https://www.aequuspharma.ca/news-releases/aequus-announces-notice-of-warrant-acceleration https://www.aequuspharma.ca/news-releases/aequus-announces-official-launch-of-zepto-capsulotomy-system-in-canada-to-be-june-1-2018 https://www.aequuspharma.ca/news-releases/aequus-announces-positive-results-for-proof-of-concept-clinical-trial-of-anti-nausea-patch https://www.aequuspharma.ca/news-releases/aequus-announces-positive-results-from-second-proof-of-concept-study-for-long-acting-aripiprazole-transdermal-patch https://www.aequuspharma.ca/news-releases/aequus-announces-positive-results-from-single-dose-bioavailability-study-of-aripiprazole-transdermal-patch https://www.aequuspharma.ca/news-releases/aequus-announces-positive-skin-irritation-results-for-once-weekly-transdermal-aripiprazole https://www.aequuspharma.ca/news-releases/aequus-announces-positive-update-on-dry-eye-product-launch-plans https://www.aequuspharma.ca/news-releases/aequus-announces-proposed-300-000-equity-financing https://www.aequuspharma.ca/news-releases/aequus-announces-proposed-800-000-equity-financing-to-next-edge-biotech-plus-fund https://www.aequuspharma.ca/news-releases/aequus-announces-proposed-equity-financings-of-up-to-c-2-750-000 https://www.aequuspharma.ca/news-releases/aequus-announces-proposed-offering-of-common-shares https://www.aequuspharma.ca/news-releases/aequus-announces-public-offering-of-convertible-debenture-units https://www.aequuspharma.ca/news-releases/aequus-announces-sale-of-zimed-pf-to-luvo-medical-technologies https://www.aequuspharma.ca/news-releases/aequus-announces-sandoz-contract-expiry-at-year-end-and-expected-health-canada-approval-for-zimed-r-pf-preservative-free https://www.aequuspharma.ca/news-releases/aequus-announces-short-term-loan https://www.aequuspharma.ca/news-releases/aequus-announces-stock-option-grant https://www.aequuspharma.ca/news-releases/aequus-announces-stock-option-grant-2 https://www.aequuspharma.ca/news-releases/aequus-announces-terms-of-public-offering-of-common-shares https://www.aequuspharma.ca/news-releases/aequus-announces-the-issuance-of-stock-options https://www.aequuspharma.ca/news-releases/aequus-announces-upsizing-of-previously-announced-bought-deal-of-units-to-4-5-million https://www.aequuspharma.ca/news-releases/aequus-announces-zimed-r-pf-now-available-in-canada https://www.aequuspharma.ca/news-releases/aequus-announces-zimed-r-pf-website-launch https://www.aequuspharma.ca/news-releases/aequus-appoints-ann-fehr-as-chief-financial-officer https://www.aequuspharma.ca/news-releases/aequus-approves-advance-notice-policy https://www.aequuspharma.ca/news-releases/aequus-awarded-growth-stage-life-sciences-company-of-the-year https://www.aequuspharma.ca/news-releases/aequus-closes-2-35-million-offering-of-convertible-debenture-units https://www.aequuspharma.ca/news-releases/aequus-closes-balance-of-775-000-equity-financing https://www.aequuspharma.ca/news-releases/aequus-closes-financing-for-gross-proceeds-of-c-1-237-500 https://www.aequuspharma.ca/news-releases/aequus-closes-financing-for-gross-proceeds-of-c-2-743-920 https://www.aequuspharma.ca/news-releases/aequus-closes-previously-announced-equity-financings https://www.aequuspharma.ca/news-releases/aequus-completes-c-2-5-million-equity-financing https://www.aequuspharma.ca/news-releases/aequus-expands-market-in-quebec-for-tacrolimus-ir https://www.aequuspharma.ca/news-releases/aequus-extends-and-enhances-commercial-agreement-to-promote-vistitan-in-canada https://www.aequuspharma.ca/news-releases/aequus-extends-commercial-agreement-for-specialty-product-tacrolimus-ir-in-canada https://www.aequuspharma.ca/news-releases/aequus-extends-commercial-agreement-for-specialty-product-tacrolimus-ir-in-canada-2 https://www.aequuspharma.ca/news-releases/aequus-forms-strategic-advisory-board-in-ophthalmology-chaired-by-dr-ike-ahmed https://www.aequuspharma.ca/news-releases/aequus-granted-chinese-patent-for-once-weekly-transdermal-aripiprazole https://www.aequuspharma.ca/news-releases/aequus-granted-european-patent-for-once-weekly-transdermal-aripiprazole https://www.aequuspharma.ca/news-releases/aequus-highlights-study-indicating-vistitan-as-the-most-effective-treatment-for-glaucoma https://www.aequuspharma.ca/news-releases/aequus-hosts-live-webinar-demonstrating-the-zepto-r-capsulotomy-system-led-by-dr-ike-ahmed https://www.aequuspharma.ca/news-releases/aequus-initiates-second-proof-of-concept-clinical-trial-of-transdermal-aripiprazole-patch https://www.aequuspharma.ca/news-releases/aequus-launches-evolve-eye-drops-to-eye-care-professionals-in-canada https://www.aequuspharma.ca/news-releases/aequus-launches-medical-cannabis-physician-research-in-us-and-canada https://www.aequuspharma.ca/news-releases/aequus-licenses-canadian-commercialization-rights-to-trokendi-xr-r-and-oxtellar-xr-r-from-supernus https://www.aequuspharma.ca/news-releases/aequus-licenses-rights-to-cannabinoid-transdermal-patch-to-treat-neurological-disorders https://www.aequuspharma.ca/news-releases/aequus-obtains-ontario-provincial-listing-for-vistitan https://www.aequuspharma.ca/news-releases/aequus-obtains-public-reimbursement-for-vistitan-in-two-additional-provinces-alberta-and-manitoba https://www.aequuspharma.ca/news-releases/aequus-partners-with-camargo-to-support-us-regulatory-strategy-for-development-programs https://www.aequuspharma.ca/news-releases/aequus-pharmaceutical-canada-announces-a-pause-in-sales-of-evolve-intensive-eyedrops-and-gel-in-canada https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-and-cdrd-announce-research-collaboration-to-improve-cannabinoid-based-therapeutics https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-announces-development-agreement-for-transdermal-aripiprazole-with-corium-international https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-announces-it-has-entered-into-a-definitive-agreement-to-acquire-teora-health-and-intends-to-promote-its-first-commercial-product-in-canada-in-2015 https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-announces-the-completion-of-the-acquisition-of-teora-health https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-announces-trading-on-otcqb https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-becomes-reporting-issuer https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-closes-4-2-million-private-placement-financing https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-inc-announces-2-0-to-4-0-million-best-efforts-financing https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-inc-closes-on-c-1-2-million-in-equity-financings-and-in-licenses-global-rights-to-intellectual-property-enabling-the-transdermal-delivery-of-aripiprazole https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-initiates-promotional-efforts-for-transplant-product-in-canada https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-initiates-promotional-efforts-for-vistitan-c-in-canada https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-lists-on-the-tsx-venture-exchange-and-appoints-new-director https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-receives-conditional-approval-to-commence-trading-on-tsx-v-exchange https://www.aequuspharma.ca/news-releases/aequus-pharmaceuticals-to-present-at-noble-capital-markets-investor-conference https://www.aequuspharma.ca/news-releases/aequus-poised-to-fill-bimatoprost-0-03-drug-shortage-in-canada https://www.aequuspharma.ca/news-releases/aequus-prepares-for-health-canada-regulatory-filing-as-partner-receives-mdsap-certificate-for-dry-eye-products https://www.aequuspharma.ca/news-releases/aequus-prepares-for-proof-of-concept-clinical-study-for-transdermal-anti-nausea-diclegis-program https://www.aequuspharma.ca/news-releases/aequus-provides-corporate-update-on-commercial-and-development-programs https://www.aequuspharma.ca/news-releases/aequus-provides-financial-year-end-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-first-quarter-2017-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-first-quarter-2018-financial-and-corporate-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-first-quarter-2019-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-fourth-quarter-and-fiscal-2016-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-fourth-quarter-and-fiscal-2017-financial-highlights-third-consecutive-quarter-of-revenue-growth https://www.aequuspharma.ca/news-releases/aequus-provides-general-update-and-2019-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-general-update-and-director-changes https://www.aequuspharma.ca/news-releases/aequus-provides-general-update-and-first-quarter-2021-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-general-update-and-first-quarter-2023-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-general-update-and-first-quarter-2024-financial-highlights-grant-stock-options-and-financing https://www.aequuspharma.ca/news-releases/aequus-provides-general-update-and-reports-record-2020-financial-results https://www.aequuspharma.ca/news-releases/aequus-provides-general-update-fiscal-2023-financial-results https://www.aequuspharma.ca/news-releases/aequus-provides-launch-update-zimed-pf https://www.aequuspharma.ca/news-releases/aequus-provides-q3-2016-financial-highlights-with-substantial-increase-in-quarter-over-quarter-revenues https://www.aequuspharma.ca/news-releases/aequus-provides-second-quarter-2017-operational-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-third-quarter-2017-operational-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-third-quarter-2019-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-third-quarter-2020-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-update-and-reports-third-quarter-2024-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-provides-update-on-delay-in-filing-annual-financial-statements https://www.aequuspharma.ca/news-releases/aequus-provides-update-on-delay-in-filing-annual-financial-statements-2 https://www.aequuspharma.ca/news-releases/aequus-provides-update-on-delay-in-filing-annual-financial-statements-3 https://www.aequuspharma.ca/news-releases/aequus-provides-update-on-warrant-acceleration https://www.aequuspharma.ca/news-releases/aequus-raises-5-2-million-through-bought-deal-financing-including-full-exercise-of-the-over-allotment-option https://www.aequuspharma.ca/news-releases/aequus-receives-approval-for-new-evolve-daily-intensive-lubricating-eye-drops-in-canada https://www.aequuspharma.ca/news-releases/aequus-receives-approval-for-new-evolve-intensive-gel-lubricating-eye-drops-in-canada https://www.aequuspharma.ca/news-releases/aequus-receives-approval-for-short-form-base-shelf-prospectus-to-raise-up-to-c-20-000-000 https://www.aequuspharma.ca/news-releases/aequus-receives-approval-from-health-canada-to-initiate-phase-1-clinical-trial-of-aripiprazole-transdermal-patch https://www.aequuspharma.ca/news-releases/aequus-receives-approval-from-health-canada-to-initiate-proof-of-concept-clinical-trial-of-anti-nausea-patch https://www.aequuspharma.ca/news-releases/aequus-receives-non-dilutive-funding-from-the-government-of-canada-to-support-aripiprazole-patch-development https://www.aequuspharma.ca/news-releases/aequus-receives-positive-fda-regulatory-guidance-for-anti-nausea-patch https://www.aequuspharma.ca/news-releases/aequus-receives-positive-formulary-decision-in-british-columbia-for-specialty-portfolio-product https://www.aequuspharma.ca/news-releases/aequus-replaces-expired-short-form-base-shelf-prospectus https://www.aequuspharma.ca/news-releases/aequus-reports-5th-consecutive-quarter-of-revenue-growth https://www.aequuspharma.ca/news-releases/aequus-reports-first-quarter-2025-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-reports-largest-quarterly-revenue-in-company-history-and-provides-management-update https://www.aequuspharma.ca/news-releases/aequus-reports-second-quarter-2023-financial-highlights-and-general-update https://www.aequuspharma.ca/news-releases/aequus-reports-second-quarter-2024-financial-highlights-and-general-update https://www.aequuspharma.ca/news-releases/aequus-reports-second-quarter-2025-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-reports-third-quarter-2021-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-reports-third-quarter-2022-financial-highlights https://www.aequuspharma.ca/news-releases/aequus-reports-third-quarter-2023-financial-highlights-and-general-update https://www.aequuspharma.ca/news-releases/aequus-resumes-trading-on-tsx-venture-exchange https://www.aequuspharma.ca/news-releases/aequus-retains-investor-relations-representative https://www.aequuspharma.ca/news-releases/aequus-signs-exclusive-distribution-agreement-with-advanced-ophthalmic-innovations-for-the-paul-r-glaucoma-drainage-device-in-canada https://www.aequuspharma.ca/news-releases/aequus-signs-exclusive-distribution-agreement-with-medicom-healthcare-for-canadian-distribution-rights-of-ophthalmic-products https://www.aequuspharma.ca/news-releases/aequus-signs-exclusive-distribution-agreement-with-scope-ophthalmics-for-canadian-distribution-rights-of-dry-eye-products https://www.aequuspharma.ca/news-releases/aequus-signs-term-sheet-for-five-preservative-free-dry-eye-products https://www.aequuspharma.ca/news-releases/aequus-signs-term-sheet-with-european-partner-for-a-preservative-free-therapeutic-in-ophthalmology https://www.aequuspharma.ca/news-releases/aequus-strengthens-clinical-experience-in-stargardt-disease-with-pediatric-ophthalmology-expertise https://www.aequuspharma.ca/news-releases/aequus-strengthens-clinical-experience-on-strategic-advisory-board-in-ophthalmology-and-adds-commercial-and-regulatory-expertise https://www.aequuspharma.ca/news-releases/aequus-successfully-completes-dosing-in-second-proof-of-concept-clinical-trial-of-transdermal-aripiprazole-patch https://www.aequuspharma.ca/news-releases/aequus-to-broaden-vistitan-reimbursement-for-patients-in-canada https://www.aequuspharma.ca/news-releases/aequus-to-present-at-bloom-burton-co-healthcare-investor-conference https://www.aequuspharma.ca/news-releases/aequus-to-present-at-bloom-burton-co-healthcare-investor-conference-on-may-1-2019 https://www.aequuspharma.ca/news-releases/aequus-to-present-at-bloom-burton-co-healthcare-investor-conference-on-may-2-2018 https://www.aequuspharma.ca/news-releases/aequus-validates-need-for-improved-delivery-methods-of-medical-cannabis https://www.aequuspharma.ca/news-releases/amendment-on-earlier-release-aequus-provides-general-update-and-first-quarter-2020-financial-highlights https://www.aequuspharma.ca/news-releases/cannaroyalty-and-aequus-pharmaceuticals-announce-joint-venture-to-develop-and-commercialize-cannabis-based-therapies-targeting-neurological-disorders https://www.aequuspharma.ca/news-releases/fda-confirms-date-to-providing-regulatory-guidance-for-aequus-anti-nausea-patch https://www.aequuspharma.ca/news-releases/issuance-of-stock-options https://www.aequuspharma.ca/news-releases/positive-preclinical-results-and-patent-allowed-for-aequus-once-weekly-transdermal-aripiprazole https://www.aequuspharma.ca/news-releases/sandoz-and-aequus-agree-to-1-year-extension-on-vistitan-in-canada https://www.aequuspharma.ca/news-releases/santen-and-aequus-enter-into-a-commercial-collaboration-in-canada https://www.aequuspharma.ca/news-releases/toby-chans-switch-study